Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia

NCT01874756 is registered in ClinicalTrials.gov with Indiana University as lead sponsor.

NCT NCT01874756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01874756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia
Lead sponsor
Indiana University
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2013
Completion date
December 31, 2017
Enrollment
95 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia